Key result
Fluvastatin significantly improved endothelium-dependent vasodilation compared with placebo (change of 108% vs -26%; P≤0.05), an effect mediated by increased nitric oxide bioavailability.
Why the study?
Does fluvastatin improve endothelium-dependent vasodilation in patients with hypercholesterolemia?
RCT (n=29)
double-blind
randomized
Does fluvastatin improve endothelium-dependent vasodilation in patients with hypercholesterolemia?
Absolute Event Rate: 108% vs -26%
p-value: p=≤0.05
Fluvastatin improves endothelial function in hypercholesterolemic patients by increasing the bioavailability of nitric oxide.
No takes yet. Share an insight, caveat, or question.
Supports fluvastatin for endothelial protection in hypercholesterolemia; extends statin evidence to nitric oxide bioavailability.
John et al. (1998) conducted an RCT in Hypercholesterolemia (n=29). Fluvastatin vs. Placebo was evaluated on Change in endothelium-dependent vasodilation (ACh 24 microg/min) (p=≤0.05). Fluvastatin significantly improved endothelium-dependent vasodilation compared with placebo (change of 108% vs -26%; P≤0.05), an effect mediated by increased nitric oxide bioavailability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: